Tamoxifen as an antioxidant and cardioprotectant

被引:24
作者
Wiseman, H
机构
[1] Department of Nutrition and Dietetics, King's College London, Kensington
来源
FREE RADICALS AND OXIDATIVE STRESS: ENVIRONMENT, DRUGS AND FOOD ADDITIVES | 1995年 / 61期
关键词
D O I
10.1042/bss0610209
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tamoxifen is widely used in the treatment of breast cancer and has been proposed as a prophylactic agent in this disease. Tamoxifen is an effective antioxidant and protects membranes and low-density lipoprotein (LDL) particles against oxidative damage. This antioxidant action is shared by endogenous and synthetic oestrogens. The ability of tamoxifen to protect LDL particles against the oxidative damage implicated in atherosclerosis may be an important factor in the reported cardioprotective action of tamoxifen in women being treated for breast cancer. In addition, tamoxifen has been found to act in a similar manner to oestrogens to lower plasma cholesterol levels. The cardioprotective action of tamoxifen may be a key factor in predicting the likely risk/benefit ratio for prophylactic tamoxifen treatment in otherwise healthy women, who have been calculated to be genetically predisposed to developing breast cancer. In the future, predisposition to breast cancer may be determined by genetic screening.
引用
收藏
页码:209 / 219
页数:11
相关论文
共 67 条
[1]   INHIBITION OF CORONARY-ARTERY ATHEROSCLEROSIS BY 17-BETA ESTRADIOL IN OVARIECTOMIZED MONKEYS - LACK OF AN EFFECT OF ADDED PROGESTERONE [J].
ADAMS, MR ;
KAPLAN, JR ;
MANUCK, SB ;
KORITNIK, DR ;
PARKS, JS ;
WOLFE, MS ;
CLARKSON, TB .
ARTERIOSCLEROSIS, 1990, 10 (06) :1051-1057
[2]  
ANDERSSON A, 1992, EUR J CLIN CHEM CLIN, V30, P377
[3]   PLASMA HOMOCYSTEINE BEFORE AND AFTER METHIONINE LOADING WITH REGARD TO AGE, GENDER, AND MENOPAUSAL STATUS [J].
ANDERSSON, A ;
BRATTSTROM, L ;
ISRAELSSON, B ;
ISAKSSON, A ;
HAMFELT, A ;
HULTBERG, B .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1992, 22 (02) :79-87
[4]  
ANKER G, 1995, INT J CANCER, V60, P365
[5]  
ARNESEN E, 1995, IN PRESS INT J EPIDE
[7]  
CARR BR, 1992, WILLIAMS TXB ENDOCRI, P733
[8]  
CHLEBOWSKI RT, 1993, CANCER, V72, P1032, DOI 10.1002/1097-0142(19930801)72:3+<1032::AID-CNCR2820721315>3.0.CO
[9]  
2-O
[10]  
DEFRIEND DJ, 1994, CANCER RES, V54, P408